Estrogen-Only Therapy After 70 Tied to 35% Lower Alzheimer's Pathology Odds in 21k-Woman Cohort
Retrospective analysis of 21,462 women links post-70 estrogen-only therapy to reduced Alzheimer's autopsy pathology and biomarkers, yet remains associational with therapy timing unlike current practice. Stronger evidence requires prospective RCTs matching modern regimens. Findings highlight need to separate historical use patterns from today's standards before altering prescribing.
Public-health impact hinges on whether modern timing and dosing replicate the autopsy signal; a large RCT starting therapy at menopause onset would be required to test prevention. Until then, clinicians should continue viewing these data as hypothesis-generating rather than actionable for dementia risk reduction.
Bruno et al.: No large-scale RCT of modern estrogen-only therapy initiated at menopause will report dementia-risk reduction by 2032.
Sources (3)
- [1]Primary Source(https://www.neurology.org/doi/10.1212/WNL.0000000000201234)
- [2]Supporting Source(https://www.whi.org)
- [3]Supporting Source(https://pubmed.ncbi.nlm.nih.gov/29366000)